- Home
- ULCC vs PHAT Comparison
ULCC vs PHAT Comparison
Compare ULCC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- PHAT
- Stock Information
- Founded
- ULCC 1994
- PHAT 2018
- Country
- ULCC United States
- PHAT United States
- Employees
- ULCC N/A
- PHAT N/A
- Industry
- ULCC Air Freight/Delivery Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- PHAT Health Care
- Exchange
- ULCC Nasdaq
- PHAT Nasdaq
- Market Cap
- ULCC 1.1B
- PHAT 942.6M
- IPO Year
- ULCC 2021
- PHAT 2019
- Fundamental
- Price
- ULCC $3.67
- PHAT $14.55
- Analyst Decision
- ULCC Hold
- PHAT Strong Buy
- Analyst Count
- ULCC 9
- PHAT 5
- Target Price
- ULCC $5.63
- PHAT $17.60
- AVG Volume (30 Days)
- ULCC 3.7M
- PHAT 957.4K
- Earning Date
- ULCC 11-05-2025
- PHAT 10-30-2025
- Dividend Yield
- ULCC N/A
- PHAT N/A
- EPS Growth
- ULCC N/A
- PHAT N/A
- EPS
- ULCC N/A
- PHAT N/A
- Revenue
- ULCC $3,729,000,000.00
- PHAT $147,190,000.00
- Revenue This Year
- ULCC $1.14
- PHAT $218.38
- Revenue Next Year
- ULCC $13.33
- PHAT $87.14
- P/E Ratio
- ULCC N/A
- PHAT N/A
- Revenue Growth
- ULCC 1.77
- PHAT 460.30
- 52 Week Low
- ULCC $2.89
- PHAT $2.21
- 52 Week High
- ULCC $10.26
- PHAT $16.08
- Technical
- Relative Strength Index (RSI)
- ULCC 40.32
- PHAT 63.47
- Support Level
- ULCC $3.70
- PHAT $14.07
- Resistance Level
- ULCC $4.09
- PHAT $15.28
- Average True Range (ATR)
- ULCC 0.26
- PHAT 1.05
- MACD
- ULCC 0.02
- PHAT 0.06
- Stochastic Oscillator
- ULCC 21.19
- PHAT 59.42
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.